Neoadjuvant Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer

Triple Negative Breast Cancer (TNBC) Clinical Trial

Official title:

A Phase Ⅱ Study to Evaluate the Efficacy and Safety of Camrelizumab Plus Chemotherapy as Neoadjuvant Therapy With Triple Negative Breast Cancer (TNBC)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05088057
• Other study ID #: 2021-TNBC-01
• Status: Recruiting
• Phase: Phase 2
• Start date: September 20, 2021
• Est. completion date: November 1, 2024

Study information

• Verified date: October 2021
• Source: Jilin University
• Contact: Aiping Shi, PhD
• Phone: 15804301451
• Email: 13364308696[@]163.com; 1172694608[@]qq.com; kjkzhaoliyuan[@]126.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and safety of Camrelizumab plus chemotherapy as neoadjuvant therapy and Camrelizumab as adjuvant therapy in participants who have triple negative breast cancer (TNBC).

Description:

After a screening phase of approximately 28 days, each participant will receive neoadjuvant study treatment (camrelizumab + chemotherapy) for approximately 24 weeks (8 cycles). Each participant will then undergo definitive surgery 2-4 weeks after the last cycle of the neoadjuvant treatment. After definitive surgery, each participant will receive adjuvant study treatment (camrelizumab) for approximately 27 weeks (9 cycles). Following adjuvant study treatment, each participant will be monitored for safety, survival and disease recurrence. The primary study hypothesis is that camrelizumab is superior to chemotherapy, in combination with chemotherapy, as measured by the rate of Pathological Complete Response (pCR), Event-free Survival (EFS) and Objective Overall Response Rate (ORR) in participants with TNBC.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: November 1, 2024
• Est. primary completion date: August 19, 2024
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. 18-70 Years, female;

2. Histologically documented Triple Negative Breast Cancer (TNBC) patients;

3. The subtypes of TNBC patients should include basal cell-like subtypes (BL1, BL2), Luminal androgenic type (LAR), and other types, such as mesenchymal type (M), mesenchymal stem cell type (MSL) and immunomodulatory type (IM);

4. Previously untreated non-metastatic (M0) TNBC, the primary tumor (T) and regional lymph node (N) combined staging determined by the investigator based on radiological and/or clinical evaluation. Stage at presentation: T1c, N1-N2; T2, N0-N2; T3, N0-N2;

5. Promising radical surgical treatment;

6. At least one measurable lesion according to RECIST 1.1;

7. Life expectancy is not less than 3 months;

8. ECOG: 0~1;

9. Adequate function of major organs meets the following requirements:

Neutrophils = 1.5×10^9/L Hemoglobin = 90g/L Platelets = 100×10^9/L Total bilirubin= 1.5 × the upper limit of normal (ULN) ALT and AST = 2.5 × ULN Serum creatinine =1.5 × ULN, Endogenous creatinine clearance =50mL/min;

10. Left ventricular ejection fraction (LVEF) =50% or = limit of normal (LLN) was evaluated by echocardiography (ECHO) or Multigated Acquisition (MUGA);

11. Women with childbearing potential who are must agree to take effective contraceptive measures during the study period and =120 days after the last administration of the study drug, and must have a negative serum pregnancy test result within 7 days prior to initiation of study drug.

12. The patient voluntarily joined the study, signed an informed consent form, had good compliance, and cooperated with follow-up;

Exclusion Criteria:

1. Has participated in an interventional clinical study with an investigational compound within 4 weeks prior to initiation of study treatment;

2. Prior treatment with anti-cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA-4), anti-programmed death-1 (anti-PD-1), and anti-PD-L1 therapeutic antibodies;

3. Has a history of invasive malignancy =5 years prior to signing informed consent except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer;

4. Active or history of autoimmune disease or immune deficiency diseases except history of autoimmune-related hypothyroidism, controlled Type 1 diabetes mellitus;;

5. Has a history of (non-infectious) pneumonitis, interstitial lung disease or uncontrollable systematicness diseases, including pulmonary fibrosis, acute lung disease, etc.;

6. Administration of a live attenuated vaccine within 30 days prior to initiation of study treatment or anticipation of need for such a vaccine during the study;

7. Has active infection (CTCAE=2) needed the treatment of antibiotic within 2 weeks prior to initiation of study treatment;

8. Has a history of serious cardiovascular disease, including myocardial infarction, acute coronary syndrome or coronary angioplasty/stent implantation/bypass grafting history in the past 6 months, and have level II-IV congestion Heart failure (CHF), or III NYHA and IV CHF history;

9. Prior allogeneic stem cell or solid organ transplantation

10. History of neurological or psychiatric disorders, including schizophrenia, severe depressive disorder, bipolar disorder, etc.;

11. Subjects with a condition requiring systemic treatment with either corticosteroids (>10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of first administration of study treatment. Inhaled or topical steroids, and adrenal replacement steroid doses > 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease.

12. History of severe hypersensitivity reactions to other monoclonal antibodies, or intravenous infusion, or Doxorubicin, or cyclophosphamide, or docetaxel;

13. Female patients during pregnancy and lactation, fertile women with positive baseline pregnancy tests or women of childbearing age who are unwilling to take effective contraceptive measures throughout the trial;

14. Any other situation evaluated by researchers.

Related Conditions & MeSH terms

• Breast Neoplasms
• Triple Negative Breast Cancer (TNBC)
• Triple Negative Breast Neoplasms

Intervention

Drug:
• Camrelizumab
200mg on Day 1 of each cycle in the neoadjuvant and adjuvant phases of the study for a total of 17 cycles (Q3W), intravenous (IV) infusion.
• Doxorubicin
60mg/m² on Day 1 of Cycles 1-4 (Q3W)of the neoadjuvant phase of the study, IV infusion.
• Cyclophosphamide
600 mg/m² on Day 1 of Cycles 1-4 (Q3W)of the neoadjuvant phase of the study, IV infusion.
• Docetaxel
75mg/m² on Day 1 of Cycles 1-4 (Q3W) or Cycles 5-8 (Q3W) of the neoadjuvant phase of the study, IV infusion;

Locations

Country	Name	City	State
China	Aiping Shi	Changchun	Jilin

Sponsors (1)

Lead Sponsor	Collaborator
Aiping Shi

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	End point of exploratory study	Correlation analysis and COX regression analysis were performed on pCR, EFS, ORR, OS of patients with basal cell-like subtypes (BL1, BL2), Luminal androgenic type (LAR), and other types.	Up to approximately 35 weeks
Primary	Pathological Complete Response (pCR)	pCR rate is defined as the percentage of participants without invasive cancer in the breast irrespective of ductal carcinoma in situ or nodal involvement following completion of neoadjuvant systemic therapy by current AJCC staging criteria assessed by the local pathologist at the time of definitive surgery in all participants	Up to approximately 12-30 weeks
Secondary	Event-Free Survival (EFS)	EFS is defined as the time from start of study treatment to any of the following events: progression of disease that precludes surgery, local or distant recurrence, second primary malignancy (breast or other cancers) or death due to any cause.	Up to approximately 2 years
Secondary	Objective Overall Response Rate (ORR)	ORR was defined as percentage of participants with best (confirmed) overall response (BOR) of either CR or PR. ORR was assessed by the investigator according to RECIST version 1.1 and is based on BOR, which is defined as best response recorded from start of study treatment until definitive surgery or disease progression.	[Time Frame: Up to approximately 12-30 weeks]
Secondary	Overall survival (OS)	OS is defined as the time from randomization to death due to any cause. Participants without documented death at the time of the analysis will be censored at the date of the last follow-up.	Up to approximately 2 years
Secondary	Adverse events (AEs)	AEs were graded according to the National Cancer Institute's Common Toxicity Criteria for Adverse Events (CTCAE) version 5.0. In general, AEs are graded according to the following: Grade 1 Mild AE Grade 2 Moderate AE Grade 3 Severe AE Grade 4 Life-threatening or disabling AE Grade 5 Death related to AE. The type, grade and frequency of AEs will be reported.	Up to approximately 35 weeks